Trial Profile
A Phase I/II Study of the Addition of Ixazomib to ONC201 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jun 2020
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dordaviprone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 27 May 2020 Status changed from recruiting to discontinued.
- 16 Apr 2018 According to the Oncoceutics media release, first patient has been treated in this study.
- 12 Apr 2018 New trial record